Physician profile
Mark D Watson
NPI 1346416153
$1,679.58
in general payments reported to CMS, 2019-2025
15 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $106 · 2021: $245 · 2022: $124 · 2023: $225 · 2024: $436 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $708.00 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Pfizer INC. | $341.28 | 2019-2025 | |
| Allergan, INC. | $298.27 | 2019-2022 | |
| Argenx US, INC. | $58.59 | 2024 | Vyvgart Hytrulo |
| Assertio Therapeutics, INC. | $54.28 | 2019 | |
| Kerecis Limited | $35.87 | 2019-2020 | |
| Vertos Medical, INC. | $31.30 | 2024 | Mild Device Kit |
| Lundbeck LLC | $23.39 | 2024 | Vyepti |
| Vericel Corporation | $22.81 | 2025 | Maci |
| Otsuka America Pharmaceutical, INC. | $20.16 | 2024 | Nuedexta |
| Amgen INC. | $20.08 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.23 | 2024 | Austedo Xr |
| Lilly USA, LLC | $16.86 | 2020 | |
| Nevro Corp. | $14.74 | 2019 | |
| Cardinal Health 200 LLC | $14.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.